all systems go..

Australian Cancer Technology ("AustCancer") (ASX:ACU) chairman Roger Aston and
managing director Paul Hopper announced from New York today that due diligence on the
proposed US$5 million Galenica Pharmaceuticals acquisition was completed satisfactorily
and final documentation signed today. The acquisition is now subject only to the approval of
AustCancer shareholders at an extraordinary general meeting on July 19th.
Galenica’s proprietary technology comprises three families of semi-synthetic immune
enhancers, or adjuvants, which are used to stimulate the immune system. Employed as
stand-alone therapeutics, or as an essential component in vaccines, these compounds have
been or are currently being used in cancer vaccines in two Phase I and one Phase I/II
clinical trials at leading cancer centres in the U.S.
Subject to shareholder approval at the July EGM, Galenica will formally become part of
AustCancer. Galenica founder Dr Dante Marciani will join AustCancer and continue to run
the business.